DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Applicants’ reply to the July 27, 2026 Office Action, filed August 27, 2026, is acknowledged. Applicants previously canceled claims 1-10. Applicant make no amendments. Thus, claim 11 is pending in this application, and is under examination.
In light of the new rejection set forth below, the finality of the July 27, 2026 Office Action is withdrawn, and a new non-final Office Action is issued herewith.
Priority
Acknowledgment is made of applicant's claim for foreign priority based on an application filed in China on April 29, 2020. It is noted, however, that applicant has not filed a certified copy of Chinese Patent Application No. CN202010356498.0 as required by 37 CFR 1.55.
Claim Rejections - 35 USC § 101
35 U.S.C. 101 reads as follows:
Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.
Claim 11 is rejected under 35 U.S.C. 101 because the claimed invention is directed to a product of nature without significantly more.
The claims recite a test kit for pancreatic neoplasm detection comprising probes, forward primers and reverse primers of hsa-miR-30c-5p, hsa-miR-24-3p, hsa-miR-23a-3p, and hsa-miR-132-3p having sequences consisting of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 14, SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 11, and SEQ ID NO: 15.
This judicial exception is not integrated into a practical application because such primers and probes of hsa-miR-30c-5p, hsa-miR-24-3p, hsa-miR-23a-3p, and hsa-miR-132-3p are naturally occurring sequences. Although the claims recite fragments of the hsa-miR sequences, the claims do not include additional elements that are sufficient to amount to significantly more than the judicial exception because, whether isolated or not, such naturally-occurring nucleic acids are deemed to fall under the judicial exception of natural products, and as such, are not patent-eligible subject matter pursuant to the Supreme Court decision in Association for Molecular Pathology v. Myriad Genetics, Inc., -- U.S. -- (June 13, 2013).
This judicial exception is not integrated into a practical application because the sequences comprised by the claimed kit are deemed to be products of nature. The claims do not include additional elements that are sufficient to amount to the hsa-miR sequences being markedly different than the judicial exceptions because the claim does not include additional elements, when considered separately and in combination, that are sufficient to be markedly different than the judicial exception.
Subject Matter Eligibility Test for Products and Processes
Step 1 - Is the Claim to a Process, Machine, Manufacture or Composition of Matter? YES.
The claims provide for a test kit for pancreatic neoplasm detection comprising probes, forward primers and reverse primers of hsa-miR-30c-5p, hsa-miR-24-3p, hsa-miR-23a-3p, and hsa-miR-132-3p having sequences consisting of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 14, SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 11, and SEQ ID NO: 15 (claim 11). Thus, the claims are directed to a statutory category (e.g., a product of nature).
Step 2A, Prong One — Does the Claim Recite an Product of Nature? YES.
The claims do not include additional elements that are sufficient to amount to significantly more than the judicial exception because, whether isolated or not, such naturally-occurring miRNA components are deemed to fall under the judicial exception of natural products, and as such, are not patent-eligible subject matter pursuant to the Supreme Court decision in Association for Molecular Pathology v. Myriad Genetics, Inc., -- U.S. -- (June 13, 2013).
In Myriad, the Supreme Court considered the patent eligibility of several claims directed to isolated DNA related to the human BRCA1 and BRCA2 cancer susceptibility genes. The Supreme Court held that certain of Myriad Genetics' claims to isolated DNA are not patent-eligible, because they read on isolated naturally-occurring DNA that is a "product of nature." The Court held that isolating a "gene from its surrounding genetic material is not an act of invention." The Supreme Court held that other claims are patent eligible, because they are limited to cDNA, which is a type of man-made DNA composition that is not naturally occurring. The Court held that "cDNA is not a 'product of nature' and is patent eligible under §101.”
Step 2A, Prong Two — Does the Claim Recite an Additional Elements that Integrate the Judicial Exception into a Practical Application? NO.
The Supreme Court has long distinguished between principles themselves, which are not patent eligible, and the integration of those principles into practical applications, which are patent eligible. However, absent are any additional elements recited in the claim beyond the judicial exceptions which integrate the exception into a practical application of the exception. The “integration into a practical application” requires an additional element or a combination of additional elements in the claim to apply, rely on, or use the judicial exception in a manner that imposes a meaningful limit on the judicial exception, such that it is more than a drafting effort designed to monopolize the exception. The claim limitations “a test kit for pancreatic neoplasm detection comprising probes, forward primers and reverse primers of hsa-miR-30c-5p, hsa-miR-24-3p, hsa-miR-23a-3p, and hsa-miR-132-3p having sequences consisting of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 14, SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 11, and SEQ ID NO: 15.” are not indicative of integration into a practical application. The above claim limitations are considered simply as the recitation of a naturally-occurring product. Thus, the claims do not provide for any element/step that integrates the law of nature into a practical application.
Step 2B - Does the Claim Recite Additional Elements that Amount to Significantly More than the Judicial Exception? NO.
The Supreme Court has identified a number of considerations for determining whether a claim with additional elements amounts to “significantly more” than the judicial exception(s) itself. The claims as a whole are analyzed to determine whether any additional element/step, or combination of additional elements/steps, in addition to the identified judicial exception(s) is sufficient to ensure that the claim amounts to “significantly more” than the exception(s).
However, the additional elements of the instant application, individually and in combination, do not amount to “significantly more” or “markedly different.” Under the Step 2B analysis, the “physical” elements of the claims are considered to be the same as those found in nature.
For example, miR-30c-5p is a salivary miRNA that can be used to screen for oral squamous cell carcinoma (abstract) (Fredsøe et al., 4 European Urology Focus 825-833 (2018)). MiR-24-3p is a urine-based microRNA that is shown to be useful in distinguishing benign prostatic hyperplasia and prostate cancer patients (abstract) ( Khodadadi-Jamayran et al., 9(16) Oncotarget 12868-12878 (2018)). Hsa-miR-23a-3p can be isolated from blood samples of patients having major depressive disorder (abstract) (Kim et al., 110 Journal of Psychiatric Research 38-44 (2019)). MiR is a stress-responding microRNA found in both humans and mice (abstract) (38 Cellular and Molecular Neurobiology 141-153 (2018)).
Further, the specification itself notes that hsa-miR-30c-5p, hsa-miR-24-3p, hsa-miR-23a-3p, and hsa-miR-132-3p are miRNA pancreatic cancer markers (page 4, first full paragraph).
Therefore, the claimed test kit for pancreatic neoplasm detection comprising probes, forward primers and reverse primers of hsa-miR-30c-5p, hsa-miR-24-3p, hsa-miR-23a-3p, and hsa-miR-132-3p having sequences consisting of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 14, SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 11, and SEQ ID NO: 15 is not deemed to be markedly different than nucleic acid sequences found in nature. Simply noting that the composition comprises probes and primers having nucleic acid sequences consisting of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 14, SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 11, and SEQ ID NO: 15 is not sufficient to distinguish the claimed sequences from naturally occurring hsa-miR-30c-5p, hsa-miR-24-3p, hsa-miR-23a-3p, and hsa-miR-132-3p having sequences consisting of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 13, SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 14, SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 11, and SEQ ID NO: 15.
Thus, when viewed both individually and as an ordered combination, the claimed elements, in addition to the identified judicial exception are found insufficient to supply an inventive concept because the elements are not deemed to be markedly different from those found in nature. Accordingly, the claims do not qualify as patent-eligible subject matter.
Conclusion
The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.
Hao et al. (U.S. Patent Application Publication No. 2014/0308674, published October 16, 2014, previously cited), disclose miRNAs, which are melanoma biomarkers, for quantification of relevant miRNAs with selectively binding probes and real-time PCR (abstract and paragraph [0015]). Hao et al. disclose that the value of miRNAs as clinical diagnostic tools are relevant to cancer, including endocrine pancreatic tumors (paragraph [0050]), as well as kits for determining biomarker miRNAs comprising probes and primer pairs (paragraph [0020]). However, Hao et al. do not disclose the claimed probe and primer sequences.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to NANCY J LEITH whose telephone number is (313)446-4874. The examiner can normally be reached Monday - Thursday 8:00 AM - 6:30 PM.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, NEIL HAMMELL can be reached at (571) 270-5919. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
NANCY J. LEITH
Primary Examiner
Art Unit 1636
/NANCY J LEITH/Primary Examiner, Art Unit 1636